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ABSTRACT
The major cause for failure of autologous stem cell transplantation for hematologic malignancies is the risk of
recurrent disease. As a result, new treatment regimens that include novel agents or combinations of agents and
approaches are needed. The current report describes a large Phase I/II, single-center trial that includes 60
patients with a variety of hematologic malignancies. These patients received a fixed dose of carboplatin (1
g/m2/d  72 hours by CI) etoposide (600 mg/m2/d  3 days) and cyclophosphamide (2 g/m2/d  3 days), plus
escalating doses of total body irradiation (TBI) (at 1000, 1200, and 1295 cGy) over 3 days. Eleven patients
received infusion of autologous marrow, 32 received peripheral blood stem cells, and 17 patients received both.
The maximum tolerated dose of this regimen was a radiation dose of 1200 cGy given in 200-cGy fractions
BID  3 days. The dose-limiting toxicity was mucositis, with 97% of patients requiring narcotic analgesia for
mouth pain. Overall treatment-related mortality was 6.7%, with 2 of the 4 deaths occurring in a group of 9
patients aged 60 and older. Responses were seen in all patient groups, but the most encouraging outcomes
were seen in 12 patients with high-risk or advanced acute myelocytic lymphoma (AML), 7 of whom remain alive
and free of disease beyond 5 years. This regimen is intensive and causes considerable mucositis but is otherwise
well tolerated and has demonstrated activity in a number of hematologic malignancies, especially AML.
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INTRODUCTION
Autologous transplantations for patients with he-
matologic malignancies have been in widespread use
since the mid-1980s. Randomized trials by Philip and
Gianni for non-Hodgkin’s lymphoma (NHL) and At-
tal et al. for multiple myeloma have established the
value of such treatment in a variety of diseases [1-5]. In
each instance, patients with a smaller quantity of che-
motherapy-responsive disease before transplantation
have had the best chance for durable remission and
cure. With the advent of peripheral blood stem cells
(PBSC) and cytokines to hasten platelet and neutro-
phil recovery, overall mortality and major morbidity
from such procedures has been reduced to as low as
2% to 3% for patients with multiple myeloma and 5%
to 10% for patients with more advanced lymphoma or
acute leukemia. For all diseases, the highest likelihood
of treatment failure results from tumor recurrence
posttransplantation. Whereas second transplantations
are an option for some patients, the results with full
allogeneic transplantations following failure after au-
tologous transplantations have been poor, especially
for adults with recurrent lymphoma or those who
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relapse within 2 years of their initial transplantation.
Outcomes following second transplantations with
nonablative regimens are encouraging but still of un-
certain value.
New transplantation approaches have included the
use of in vivo purging of CD-20–expressing lympho-
mas by administration of rituximab antibody therapy
during salvage and stem cell mobilization, as well as
the use of vaccines and antibody therapy posttrans-
plantation [6-8]. Although these therapies hold prom-
ise and offer novel and non–cross-resistant ap-
proaches, they also have been accompanied by a
reduction in efforts to develop improved transplanta-
tion-conditioning regimens. Whereas current pro-
grams to reduce toxicity with agents such as protegrin
and keratinocyte growth factor are important and
valuable attempts at reducing morbidity and mortal-
ity, signiﬁcant improvements in survival for these pa-
tients more likely will be derived from the addition of
new agents into standard conditioning regimens or
new drug combinations [9,10]. It is especially notable
that new regimens that combine total body irradiation
(TBI) with additional chemotherapy agents have not
been explored in recent years, in part because of the
increased incidence of secondary leukemia and myelo-
dysplasia that has been seen primarily in patients
with low-grade NHL. Whereas there is little doubt
that TBI has contributed to the development of sec-
ondary tumors in some of these patients, it is more
likely that therapy received before stem cell collection
and subsequent transplantation have been of greater
signiﬁcance [11-18]. It also is worth noting that sec-
ondary malignancies remain uncommon complica-
tions of autologous transplantations for patients with
intermediate and high-grade lymphomas, Hodgkin’s
disease, and acute leukemia, in contrast to the much
more common problem of death caused by disease
recurrence.
In an effort to develop a more effective condition-
ing regimen, the study described here was developed
and implemented in the early 1990s and previously
reported in abstract form. The current report de-
scribes our experience with a phase I/II trial in pa-
tients with a minimum follow-up of 5 years using a
novel combination of cyclophosphamide, etoposide,
carboplatin, and TBI in patients with a spectrum of
hematologic malignancies. This report provides infor-
mation regarding the toxicity and efﬁcacy of this reg-
imen and compares these results with other commonly
used autologous transplantation regimens.
PATIENTS AND METHODS
Patients
From October 1992 to September 1996, 60 pa-
tients with advanced hematologic malignancies were
enrolled on this expanded phase I/II trial. Eligible
patients ﬁrst included those with acute leukemia at
high risk (required second induction therapy to
achieve complete response (CR) or with extramedul-
lary disease at presentation) or subsequent complete
remission; NHL that was progressive or recurrent
after at least 1 prior course of multiagent chemother-
apy; multiple myeloma following initial or salvage
chemotherapy; and Hodgkin’s disease in relapse or
beyond a second complete remission. Additional eli-
gibility criteria included age 16 years and physio-
logic age 65 years, Eastern Cooperative Oncology
Group performance status of 0-2, white blood cell
count1500/L, neutrophil count500/L, platelet
count 50,000/L, aspartate transaminase and biliru-
bin 2 times normal, serum creatinine 2.0 mg/dL
or creatinine clearance 60 cc/min, pulmonary diffu-
sion capacity 50% predicted, and negative human
immunodeﬁciency virus and hepatitis B surface anti-
gen. Patients with serious medical or psychiatric ill-
ness that would prevent informed consent or general
anesthesia; uncontrolled or severe cardiovascular dis-
ease including recent (6 months) myocardial infarc-
tion or congestive heart failure; any active, uncon-
trolled bacterial, viral, or fungal infection; or an active
duodenal ulcer were excluded from enrollment. All
patients signed informed-consent documents re-
viewed and approved by the UNC Committee for the
Protection of the Rights of Human Subjects.
Treatment Plan
Patients had an indwelling central venous catheter
placed before initiation of treatment. In patients with
acute leukemia, stem cells were harvested after the
patient achieved complete remission. No leukemia
patients had stem cells collected in initial remission
for use following a subsequent relapse. In other ma-
lignancies, stem cell harvest was accomplished follow-
ing salvage chemotherapy and before initiation of the
conditioning regimen. Initial patients underwent bone
marrow harvest, but PBSC were routinely used to
rescue patients enrolled since 1994. If the collected
dose of CD34 cells was 2  106/kg, patients re-
ceived a combination of marrow and PBSC as previ-
ously described [19].
High-risk patients with acute leukemia underwent
transplantation in complete remission following initial
induction and consolidation (for patients with ex-
tramedullary disease at presentation or persistent leu-
kemia on the day 14 marrow) or following re-induc-
tion of remission for relapsed patients. Other
hematologic malignancy patients received pretrans-
plantation salvage therapy to reduce their tumor bur-
den before high-dose chemotherapy whenever possi-
ble.
The preparative regimen is detailed in Table 1. It
T. C. Shea et al.
444
was decided to ﬁx the dose of carboplatin, because data
suggested that dose escalation beyond the range of
1000 mg/m2 was of uncertain value, and that this dose
was unlikely to exacerbate the mucositis or gastroin-
testinal and pulmonary toxicity generally observed
with TBI-based regimens. Thus, a ﬁxed dose of car-
boplatin along with already-high doses of etoposide
and cyclophosphamide were thought likely to allow
escalation of TBI into its optimally effective range,
especially for acute myelocytic leukemia (AML) pa-
tients, while not generating the toxicities of veno-
occlusive disease (VOD) or renal dysfunction reported
with higher doses of carboplatin. Patients received
intravenous hydration at a minimum of 150 cc/m2/h
during chemotherapy and for a minimum of 24 hours
following the completion of chemotherapy (days 5
through 1). Patients did not routinely receive blad-
der irrigation or mesna therapy.
TBI doses were escalated according to the schema
in Table 2. This article will include detailed outcomes
of the 60 patients treated at 1000, 1200, and 1295 cGy.
Dose-limiting toxicity (DLT) was deﬁned as irrevers-
ible grade 3 or 4 nonmyeloid toxicity according to the
NCI Cancer Therapy Evaluation Program Common
Toxicity Criteria (version 2.0, BMT-Speciﬁc Adverse
Events, DCTD, NCI, DHHS, April 30, 1999).
Criteria for Response
The following deﬁnitions were used when assess-
ing response. Clinical CR was deﬁned as the disap-
pearance of all measurable disease signs, symptoms,
and biochemical changes related to the tumor, for 4
weeks, during which no new lesions appeared. A par-
tial response was deﬁned as a reduction 50% in the
sum of the products of the perpendicular diameters of
all measurable lesions lasting 4 weeks, during which
no new lesions appear and no existing lesions enlarge.
Stable disease was characterized as 50% reduction
and 25% increase in the sum of the products of 2
perpendicular diameters of all measured lesions and
the appearance of no new lesions for 8 weeks. Dis-
ease progression was described as an increase in the
product of 2 perpendicular diameters of any measured
lesion by 25%, or the appearance of new areas of
disease. Increasing symptoms alone did not constitute
progression, although their appearance generated a
new evaluation of the extent of disease. A complete
response for AML and acute lymphoblastic leukemia
(ALL) patients constituted elimination of all cytoge-
netic and morphologic evidence of leukemia with re-
covery of platelet counts to 50,000/L without
transfusion for a minimum of 30 days’ posttransplan-
tation.
RESULTS
Patients
Sixty patients ranging in age from 22 to 65 were
enrolled on this phase I protocol. Thirty-six women
and 24 men received marrow (n  11), PBSC (n 
32), or both (n  17). The initial 11 patients received
bone marrow, and subsequent patients received PBSC
if adequate cells could be collected, or marrow alone
or marrow plus PBSC if the PBSC yield was2 106
CD34 cells/kg. Patients had either AML, ALL, NHL,
multiple myeloma, or Hodgkin’s disease. Seven of 10
patients with low-grade NHL, 9 of 20 with interme-
diate- (IGL) or high-grade (HGL)-NHL, and 3 of 5
with Hodgkin’s disease had marrow involvement at
some time before transplantation. Additional patient
characteristics are provided in Table 3.
Treatment-Related Mortality
Eight patients died before day 100 posttransplan-
tation. Four deaths were treatment-related, and 4 pa-
tients—2 patients with multiple myeloma and 2 pa-
tients with IGL-NHL—died from progressive
disease. The treatment-related deaths occurred at a
median of 17 days’ posttransplantation and were pri-
marily related to sepsis and resultant multisystem or-
gan failure. One 62-year-old man with AML died on
day 26 after requiring ventilatory support and he-
Table 1. Preparative Regimen MTD
Drug
Dose
(mg/m2/d) Route
Day
8 7 6 5 4 3 2 1
Cyclophosphamide 2000 IV qd  3 ● ● ●
Etoposide 600 IV over 4 hrs qd  3 ● ● ●
Carboplatin 333 CIVI qd  72 hrs ● ●
*TBI 200 cGy bid  3 d ● ● ●
*MTD dose.
Table 2. TBI Dose Escalation
Level
Total Dose
(cGy)
Fraction S bid
(cGy)
Number of
Patients
1 1000 5 (200) 4
2* 1200 6 (200) 34
3 1295 7 (185) 22
*MTD dose.
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modialysis. The only positive culture in this patient
was a tracheal aspirate for methicillin-resistant Staph-
ylococcus aureus. A 48-year-old woman with Hodgkin’s
disease developed aspiration pneumonia with cardio-
pulmonary arrest on day 41. This progressed to in-
clude renal failure requiring hemodialysis, and she
died on day 49 of refractory hypotension and respira-
tory failure. A 66-year-old man with IGL-NHL de-
veloped atrial ﬁbrillation, sepsis, and subsequent renal
failure on day 1. He progressed to respiratory failure
on day 6, refused ventilatory support, and died fol-
lowing the initiation of comfort-care measures. A 52-
year-old-man man with IGL-NHL developed a sepsis
syndrome and underwent liver biopsy for a suspicion
of fungal disease. The biopsy was nondiagnostic and
complicated by a liver laceration and severe hemor-
rhage. All cultures were negative. The patient failed to
respond to aggressive volume resuscitation and anti-
biotic therapy, and died from multiorgan failure on
day 8. Two deaths occurred in patients treated with
1200 cGy (2/34 [5.9%]) and 2 deaths occurred follow-
ing 1295 cGy (2/22 [9.1%]). Two of these 4 treat-
ment-related deaths occurred in a group of 9 patients
who were older than age 60 (22%) vs 2 of 51 in
patients younger than age 60 (3.9%). It is also notable
that 2 of the 4 treatment-related deaths occurred in a
group of 6 patients treated for refractory large-cell
NHL.
Grade III-IV Nonhematologic Toxicities/DLT
Initially, a dose-escalation scheme was employed
with 3 patients in the ﬁrst cohort followed by dose
escalation if no DLT was observed. A fourth patient
was added at a later time to dose level 1 (1000 cGy)
when prior radiation therapy limited his ability to
receive a total dose of 1000 cGy of TBI. At dose level
2 (1200 cGy), DLT was identiﬁed in 1 of the ﬁrst 3
patients, so a second cohort of 3 patients was added
before expansion into level 3 (1295 cGy). Once the
maximum tolerated dose (MTD) was identiﬁed, it was
planned to expand the cohort enrolled at the MTD
and pursue a larger Phase II study. Whereas there was
no frank excess in irreversible grade 4 nonhematologic
toxicity or deaths at dose level 3 (2/22 TRM deaths),
the degree of mucositis was severe and further accrual
at that dose level of sufﬁciently unclear beneﬁt that a
decision was made to return to dose level 2 as the
MTD (Table 4). One patient experienced grade 2
mucosal toxicity, and 59 patients experienced grade 3
or 4 toxicity with inability to eat solid foods and
obvious mucosal hemorrhage. One patient suffered
from grade 4 toxicity and required intubation for air-
way protection. Ninety-eight percent of patients (59
of 60) required parenteral narcotics for a median of 14
days, and 97% received total parenteral nutrition
(TPN) for a median of 17 days. TPN was initiated
following a 10% loss in baseline body weight or in-
ability to eat solid food for more than 7 days. Further
details are provided in Table 4. While not statistically
signiﬁcant, the duration and severity of grade 3 and 4
mucositis appeared worse following 1295 cGy than at
1200 cGy. For this reason and because of the overall
intensity of the regimen, it was felt that 1200 cGy was
the appropriate MTD in conjunction with the other 3
drugs.
Additional toxicities are detailed in Table 5 and
Table 6. The extent of organ toxicity observed was not
unexpected given the intensity of this regimen. The
median decrease in cardiac ejection fraction was 4%.
Seven of 52 evaluable patients (13%) experienced a
20% drop in their cardiac ejection fraction to sub-
normal values of 50% posttransplantation. All pa-
Table 4. Mucositis
TBI Dose
Narcotic
Use
(%)
TPN
Use
(%)
Narcotic
Duration
(days)
TPN
Duration
(days)
1000 4 (100) 4 (100) 12 25
1200 33 (97) 33 (97) 16 16
1295/1300 22 (100) 22 (100) 14 17
Total 59 (98) 59 (98) 15 17
Table 3. Patient Characteristics and Pretreatment Diagnosis and
Disease Phase
Patient Characteristics
Stem Cell Source n
Bone Marrow 11
Peripheral Blood 32
Both 17
Total 60
Gender
Female 24 (40%)
Male 36 (60%)
Age (median, range)
48 (22–65)
Pretreatment Diagnosis and Disease Phase
Total CR1 >CR1
ALL 3 1 2
AML 12 4 8
Total CR PR RD
Marrow
Involvement
LGL-NHL 10 0 9 1 7
LGL/HGL-NHL 20 2 12 6 9
Hodgkin’s disease 5 1 4 0 3
Multiple myeloma 10 0 10 0 NA
Pretreatment Age-Adjusted IPI
Total 0 1 2 3
LGL-NHL 10 0 6 3 1
IGL/HGL-NHL 20 0 12 7 1
*ALL, acute lymphoblastic leukemia, LGL-NHL, low-grade
NHL, IGL/HGL, intermediate and high-grade NHL.
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tients with cardiac dysfunction except 1 improved with
appropriate treatment and returned to baseline or
near-baseline function over 3 to 6 months. Six patients
required intubation in the setting of sepsis and mul-
tiorgan failure or alveolar hemorrhage (1 patient).
The median percentage drop in predicted pulmonary
diffusion capacity (DLCO) was 10.5% (P  .0001).
Other life-threatening, but nonfatal, side effects
included a pericardial effusion with tamponade requir-
ing emergent drainage and 1 episode of diffuse alve-
olar hemorrhage. One patient developed grade 4
VOD, 5 patients required dialysis in the setting of
sepsis and multiorgan failure, and 1 additional patient
required dialysis in the absence of multiorgan failure
or concurrent infection; no patient required long-
term dialysis. Late toxicity included 3 patients who
developed myelodysplastic syndromes (MDS). All 3
patients carried a diagnosis of LGL-NHL and had
extensive, prior chemotherapy before undergoing
transplantation. Two patients had 3 prior therapies,
and 1 had 4; 2 of the 3 patients had prior involved ﬁeld
irradiation and 2 had inadequate stem cell yields re-
quiring them to receive both PBSC and marrow. Two
of these patients were mobilized with 2.5 g/m2 of
cyclophosphamide plus prednisone and granulocyte-
colony stimulating factor (G-CSF), and the third pa-
tient received 2 g/m2 cyclophosphamide and 2 g/m2
etoposide plus G-CSF. MDS was diagnosed at 29, 39,
and 49 months’ posttransplantation. Two of these
patients have since died from progressive NHL, and 1
died from disseminated herpes virus infection. One
additional patient has since developed resectable pros-
tate cancer at age 54, 5 years following his transplan-
tation.
Hematologic Toxicity and Engraftment
Fifty-eight patients were evaluable for engraft-
ment as described in Table 7. Median time to recovery
to an absolute neutrophil count (ANC) 500 and
platelets 20,000 without transfusion were 16.5 and
35 days for patients receiving bone marrow infusions
and 10 and 12 days for patients receiving PBSC.
These values were signiﬁcantly shorter for patients
receiving PBSC than marrow (P  .05), as was the
duration of neutrophil, but not platelet recovery,
when comparing infusion of both marrow and PBSC
to marrow alone. Patients infused with both PBSC
and marrow recovered neutrophils and platelets at a
median of 11.5 and 18.5 days, respectively. The num-
ber of platelet, but not RBC, transfusions was fewer
for patients receiving marrow than those receiving
PBSC.
Response
Whereas the purpose of this trial was to evaluate
the toxicity and deﬁne the MTD of this regimen in a
group of patients with a variety of hematologic malig-
nancies, the long follow-up of these patients makes it
worthwhile to include 5-year disease-free (27%) and
overall survival (35%) for both the entire group and
different patient subsets (Figure 1, Table 8). The
subsets of patients are too small for ﬁrm conclusions
regarding outcome, but 58% of patients with AML, all
Table 5. Grade 3–4 Nonhematologic Toxicities
TBI Dose n
Hepatic
(n  59)
Pulmonary
(n  56)
Renal
(n  59)
Cardiac
(n  52)
TRM*3 (%) 4 (%) 3 (%) 4 (%) 3 (%) 4 (%) †EF > 20%
1000 4 1 (25) 0 0 0 0 0 0 0
1200 34 9 (26) 1 (3) 0 2 (6) 1 (3) 4 (11) 4 (12) 2 (6)
1295 22 9 (41) 0 0 2 (9) 1 (5) 1 (5) 3 (14) 2 (9)
Total 60 19 (32) 1 (2) 0 4 (7) 2 (3) 5 (8) 7 (13) 4 (7)
Age > 60, 2/9
Age < 60, 2/51
*TRM, treatment-related mortality.
†This includes 7 patients with a posttransplant EF of 50% or less.
Table 6. Organ Toxicity (Median Values)
TBI Dose
EF DLCO DLCO % predicted
Pre (n) Post (n) Pre (n) Post (n) Pre (n) Post (n)
1000 63.5 (4) 55 (3) 21.1 (4) 19.5 (2) 68.5 (4) 55.5 (2)
1200 59 (33) 57.5 (31) 14.8 (32) 13.7 (30) 63 (32) 52 (24)
1295 60.5 (22) 57 (19) 16 (22) 13.4 (18) 62.5 (22) 54 (19)
Total 61 (59) 57 (53) 16 (58) 13.7 (50) 63.5 (58) 53 (45)
*P < .0001 *P < .0001
*Paired differences are signiﬁcant—Wilcoxon sign-rank test.
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but 4 of whom had disease beyond CR1, remain alive
and disease-free at 5 years. There were no long-term
disease-free survivors in the group of patients with
multiple myeloma or ALL. Twenty percent of pa-
tients with low-grade NHL and 25% of patients with
intermediate- and high-grade disease, including 1 of 6
patients with refractory large-cell NHL at the time of
transplantation, remain alive and disease-free at 5
years. These results also include 3 late deaths seen in
patients with low-grade NHL who developed myelo-
dysplasia and secondary leukemia between 29 and 49
months following transplantation.
DISCUSSION
The most common cause for failure for patients
undergoing an autologous stem cell transplantation is
recurrence of disease. Whereas there is debate as to
the role of the infusion of tumor cells administered
with stem cells for patients with leukemia, multiple
myeloma and low-grade lymphomas, the majority of
patients relapse at sites of prior disease, suggesting an
inadequate antitumor effect of the conditioning regi-
men. For this reason, we were interested in evaluating
the use of a novel conditioning regimen that added a
platinum compound to the cyclophosphamide/etopo-
side/TBI regimen in use by several centers [8,20-22].
The goal was to provide an enhanced antitumor effect
based on the use of platinum compounds for salvage
treatment in patients with NHL and Hodgkin’s dis-
ease. Here, we show that this regimen is well tolerated
in patients younger than age 60. The treatment-re-
lated mortality in this group was 3.9% and compares
favorably with that found using Cy/TBI- or Cy/VP-
16/TBI–conditioning regimens. Engraftment of
white cells and platelets was comparable with other
reports using either bone marrow or blood stem cells.
Likewise, the generally transient drop in both DLCO
(10.5%) and cardiac ejection fraction (4%) suggests
that this regimen has acceptable toxicity in otherwise-
healthy transplantation candidates with adequate or-
gan function. At the same time, the increased toxicity
observed with this regimen in older patients has
caused us to limit its use to patients younger than age
of 60 without pre-existing pulmonary or cardiac func-
tion. It also should be pointed out that the use of
high-dose BCNU in non–TBI-containing transplant
regimens is associated with a signiﬁcantly higher in-
cidence of interstitial pneumonitis than is observed
with this or other TBI-based treatments [23-25].
Because this was primarily a phase I trial, we iden-
tiﬁed an MTD associated with this therapy. The dose-
limiting toxicity of this regimen has been the occur-
rence of severe stomatitis, necessitating near universal
use of parenteral narcotics. Whereas the use of TPN
in such patients is dependant on less-easily quantiﬁ-
able factors such as their pre-existing nutritional sta-
tus, we have found that the more rapid neutrophil
recovery afforded by the use of PBSC has led us to use
TPN less commonly in the more recently treated
patients than those enrolled earlier in the course of
this trial. The availability of new agents to decrease
mucositis such as keratinocyte growth factor or pro-
tegrin therapies is likely to further reduce the inci-
dence of this serious and dose-limiting complication
[9,10]. The muscositis seen in these patients was felt to
be primarily the result of etoposide and TBI rather
than carboplatin, which has not been associated with
signiﬁcant mucosal damage when used in high doses
as a single agent [26-28]. It is appreciated that there
were no quantiﬁable differences in organ or mucosal
toxicities between the 2 highest dose levels as identi-
ﬁed in Tables 4, 5, and 6, and that 1295 cGy could be
used in this regimen. Nevertheless,1200 cGy of TBI
along with the other 3 agents was felt sufﬁciently
intense as to be identiﬁed as the MTD, while provid-
ing a slightly greater margin of safety than would have
1295 cGy. The other toxicities found in this trial were
sporadic and not unusual for conditioning regimens
used in autologous stem cell transplantation. Despite
the use of carboplatin with the conditioning regimen,
we did not ﬁnd an increased incidence of VOD or
renal dysfunction in patients treated in this trial com-
pared with those treated with other TBI-containing
regimens.
Despite wide variation in intensity, toxicity, and
chemotherapeutic agents, there have been no prospec-
tive trials comparing the outcomes of patients treated
with different conditioning regimens in comparable
patient populations. This has resulted in phase II com-
parisons based on registry or other historical data sets,
which has led to the conclusion that whereas differ-
ences in morbidity and treatment-related mortality
have been observed, overall differences in outcome
have not been apparent [29-33]. Thus, studies such as
this remain hypothesis-generating and provide leads
for potential future trials but are not, in and of them-
selves, deﬁnitive. Despite our hypothesis that the ad-
dition of a platinum compound would improve the
survival for patients with lymphoid malignancies, we
found that the outcome for patients with NHL did not
Table 7. Engraftment (Median Values)
n
Days to
ANC > 500
Days to
Last
Platelets
Number of
RBCs
Transfused
Number of
Platelets
Transfused
PBSC 31 10* 11* 8 6*
BMT 11 18 43 12 14
Both 16 12† 23.5 10 13
All 58 11 17 9 8
Wilcoxon two-group test.
*Adjusted P  .05, comparing PBSC to BMT.
†Adjusted P  .05, comparing BMT to both.
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appear to be signiﬁcantly different compared with
other TBI-based regimens. However, patients with
AML may have a better outcome using this condition-
ing regimen compared with those treated with Cy/
TBI or Bu/Cy [34,35]. This result is consistent with
the single-agent activity demonstrated by Myers [27]
and Martinez [28] with carboplatin in relapsed AML.
Clearly, this study was not powered to detect a differ-
ence in subgroup analysis and while intriguing, this
ﬁnding will need to be validated in a larger trial. It is
Figure 1. Probability of (A) relapse-free or (B) overall survival for all 60 patients by disease group. ALL, solid line; acute myeloid or acute
promyelocytic leukemia (AML or APL), dashed line; LGL-NHL, dotted line; Hodgkin’s disease, intermediate- or high-grade NHL (HD,
ILG-NHL or HGL-NHL) dotted-dashed line; multiple myeloma (MM) thick dotted-dashed line.
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important to note, however, that these results are
more mature than many phase I or II trials in that the
minimum follow-up was 5 years. Thus, both toxicity
and efﬁcacy data should be accurate and stable for all
but the low-grade NHL patients who remain in re-
mission at this time.
One of the criticisms of this conditioning regimen
could be the concern with second malignancies or
MDS that have been found in patients with low-grade
lymphomas receiving TBI. This has not been seen in
all studies, and whereas it is likely that the DNA
damage induced by TBI is contributory to subsequent
evolution of dysplastic or leukemic clones, the occur-
rence of secondary leukemia and MDS appears to be
primarily caused by other factors such as the type and
extent of prior therapy and pre-existing chromosomal
damage [10-14]. Nevertheless, the incidence of MDS/
AML observed in these low-grade NHL patients does
remain a concern, because each of the fatal cases in
this study developed in the group of 10 patients (6 of
whom remain alive and 5 of whom are disease-free
beyond 5 years) treated for this disease. This has led to
an actual incidence of 30% for that group and 0 of 14
for those patients with other diseases surviving beyond
5 years. These data suggest that like any autologous
transplantation in heavily pretreated patients, this reg-
imen may be associated with the subsequent develop-
ment of MDS and should be used with caution in
patients with low-grade NHL. On the other hand, the
potential beneﬁt of TBI should not be discarded from
use, particularly in aggressive lymphomas and leuke-
mias in the absence of controlled trials.
Lastly, whereas comparisons of outcomes between
this regimen and others that are commonly in use for
autotransplantation of patients with hematologic dis-
eases is difﬁcult, the components of these different
regimens can be compared. For example, the dose of
cyclophosphamide used in the regimen pioneered by
the City of Hope and Stanford and widely used in the
Southwest Oncology Group is 100 mg/kg, or about
60% of the dose used in this article [21]. That same
regimen uses a dose of 60 mg/kg, or about 20% more
VP-16 than the current study, and an identical 1200-
cGy dose of TBI. The inclusion of 1000 mg/m2 of
carboplatin and 30% more cyclophosphamide in the
UNC regimen suggests that this is appreciably more
intense, and potentially more effective without addi-
tional grade 4 or fatal toxicity compared with the
regimen described by Nademanee [19-21]. Whereas it
is important to emphasize the merits of new ap-
proaches in treating these patients and to incorporate
new modalities such as cell selection and radiolabeled
and unlabelled antibodies into their treatment regi-
mens, it is just as important to underscore the central
role of the conditioning regimen in these therapies
[6-8,36-38]. The lack of beneﬁt from some of the new
approaches recently was underscored by the report
from Stewart in multiple myeloma patients in which
the use of CD34 selection as a means for purging
plasma cells from the infusion product was ineffective
in prolonging disease-free or overall survival in a ran-
domized trial [36]. Likewise, the use of PBSC as op-
posed to bone marrow for support of patients under-
going a BEAC-based transplantation-conditioning
regimen did not alter the relapse rate and either over-
all or disease-free survival for these patients [37].
Whereas it appears that these more recent approaches
have reduced toxicity, duration of hospitalization, and
time to neutrophil and platelet engraftment, death
from disease recurrence remains the central problem
following autologous transplantation. Assuming that
dose intensity remains the cornerstone of both autol-
ogous and allogeneic transplantation for such patients,
it is clear that the regimen described in this report
offers a more intensive approach than the majority of
currently available treatment programs. Whether such
an approach is more effective than less-toxic and in-
tensive alternatives remains to be seen with carefully
designed phase II or III trials that incorporate well-
deﬁned patient populations, different regimens, and
new adjunctive therapies.
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